Marina Biotech inks license deal to deliver genome editing technology
The agreement is notable in that it provides an exclusive access to Marina’s SMARTICLES and DiLA2 platforms for a different gene editing field than was announced on February
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.
Major amendments to the protocol include the addition of talimogene laherparepvec (Imlygic) as an option for use as comparator. The amended protocol also extends eligibility to include Stage